Freire Antônio Fernando Diniz, Nicz Pedro Felipe Gomes, Ribeiro Henrique Barbosa, Filippini Filippe Barcellos, Accorsi Tarso Duenas, Liberato Gabriela, Nomura Cesar Higa, Cassar Renata de Sa, Vieira Marcelo Luiz Campos, Mathias Wilson, Pomerantzeff Pablo Maria Alberto, Tarasoutchi Flavio, Abizaid Alexandre, Kalil Filho Roberto, de Brito Fábio Sândoli
Department of Interventional Cardiology, Heart Institute of University of São Paulo (InCor), São Paulo, Brazil.
Front Cardiovasc Med. 2023 Jun 14;10:1175600. doi: 10.3389/fcvm.2023.1175600. eCollection 2023.
Acute kidney injury (AKI) is frequently observed after transcatheter aortic valve implantation (TAVI). Of note, it is associated with a threefold increase in all-cause and cardiac death. We propose a new non-contrast strategy for evaluating and performing the TAVI procedure that can be especially valuable for patients with aortic stenosis (AS) and chronic kidney disease (CKD) to prevent AKI.
Patients with severe symptomatic AS and CKD stage ≥3a were evaluated for TAVI using four non-contrast imaging modalities for procedural planning: transesophageal echocardiogram (TEE), cardiac magnetic resonance, multidetector computed tomography (MDCT), and aortoiliac CO angiography. Patients underwent transfemoral (TF) TAVI using the self-expandable Evolut R/Pro, and the procedures were guided by fluoroscopy and TEE. Contrast MDCT and contrast injection at certain checkpoints during the procedure were used in a blinded fashion to guarantee patient safety.
A total of 25 patients underwent TF-TAVI with the zero-contrast technique. The mean age was 79.9 ± 6.1 years, 72% in NYHA class III/IV, with a mean STS-PROM of 3.0% ± 1.5%, and creatinine clearance of 49 ± 7 ml/min. The self-expandable Evolut R and Pro were implanted in 80% and 20% of patients, respectively. In 36% of the cases, the transcatheter heart valve (THV) chosen was one size larger than the one by contrast MDCT, but none of these cases presented adverse events. Device success and the combined safety endpoint (at 30 days) both achieved 92%. Pacemaker implantation was needed in 17%.
This pilot study demonstrated that the zero-contrast technique for procedural planning and THV implantation was feasible and safe and might become the preferable strategy for a significant population of CKD patients undergoing TAVR. Future studies with a larger number of patients are still needed to confirm such interesting findings.
经导管主动脉瓣植入术(TAVI)后常观察到急性肾损伤(AKI)。值得注意的是,它与全因死亡和心源性死亡增加两倍相关。我们提出一种新的非对比策略来评估和实施TAVI手术,这对患有主动脉瓣狭窄(AS)和慢性肾脏病(CKD)的患者预防AKI可能特别有价值。
对有严重症状性AS且CKD分期≥3a的患者,使用四种非对比成像模式进行TAVI评估以用于手术规划:经食管超声心动图(TEE)、心脏磁共振、多排螺旋计算机断层扫描(MDCT)和腹主动脉髂动脉CO血管造影。患者采用经股动脉(TF)途径,使用自膨胀式Evolut R/Pro进行TAVI,手术由荧光透视和TEE引导。在手术过程中的某些检查点使用对比剂MDCT和对比剂注射,采用盲法以确保患者安全。
共有25例患者采用零对比技术进行了TF-TAVI。平均年龄为79.9±6.1岁,72%为纽约心脏协会(NYHA)心功能Ⅲ/Ⅳ级,平均胸外科医师协会预测风险(STS-PROM)为3.0%±1.5%,肌酐清除率为49±7 ml/min。自膨胀式Evolut R和Pro分别植入了80%和20%的患者。在36%的病例中,所选的经导管心脏瓣膜(THV)比对比剂MDCT测量的大一号,但这些病例均未出现不良事件。器械成功率和联合安全终点(30天时)均达到92%。17%的患者需要植入起搏器。
这项前瞻性研究表明,用于手术规划和THV植入的零对比技术是可行且安全的,可能成为大量接受TAVR的CKD患者的首选策略。仍需要更多患者参与的未来研究来证实这些有趣的发现。